Sentinel lymph node biopsy in patients with ductal carcinomain situ: systematic review and meta-analysis | Zendy

Matthew G. Davey | Zendy; Colm O’Flaherty | Zendy; Eoin F. Cleere | Zendy; Aoife Nohilly | Zendy; James Phelan | Zendy; Evan Ronane | Zendy; Aoïfe Lowery | Zendy; Michael J. Kerin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sentinel lymph node biopsy in patients with ductal carcinomain situ: systematic review and meta-analysis

Author(s) -

Matthew G. Davey,

Colm O’Flaherty,

Eoin F. Cleere,

Aoife Nohilly,

James Phelan,

Evan Ronane,

Aoïfe Lowery,

Michael J. Kerin

Publication year - 2022

Publication title -

bjs open

Language(s) - English

Resource type - Journals

ISSN - 2474-9842

DOI - 10.1093/bjsopen/zrac022

Subject(s) - medicine , sentinel lymph node , ductal carcinoma , biopsy , breast cancer , odds ratio , confidence interval , axilla , diagnostic odds ratio , carcinoma , carcinoma in situ , radiology , surgery , cancer

Axillary lymph node status remains the most powerful prognostic indicator in invasive breast cancer. Ductal carcinoma in situ (DCIS) is a non-invasive disease and does not spread to axillary lymph nodes. The presence of an invasive component to DCIS mandates nodal evaluation through sentinel lymph node biopsy (SLNB). Quantification of the necessity of upfront SLNB for DCIS requires investigation. The aim was to establish the likelihood of having a positive SLNB (SLNB+) for DCIS and to establish parameters predictive of SLNB+.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research